Page 96 - 2021_06-Haematologica-web

A. Nagler et al. References
1. Juliusson G, Karlsson K, Lazarevic VL, et al. Hematopoietic stem cell transplantation rates and long-term survival in acute myeloid and lymphoblastic leukemia. Cancer. 2011;117(18):4238-4246.
2. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007; 109(3):944.
3. Gupta V, Richards S, Rowe J. Allogeneic, but not autologous, hematopoietic cell trans- plantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis. Blood. 2013; 121(2):339.
4.D’Souza A, Lee S, Zhu X, Pasquini M. Current use and trends in hematopoietic cell transplantation in the United States. Biol Blood Marrow Transplant. 2017;23(9):1417- 1421.
5. Mancusi A, Ruggeri L, Velardi A. Haploidentical hematopoietic transplanta- tion for the cure of leukemia: from its biolo- gy to clinical translation. Blood. 2016;128 (23):2616.
6. Henslee-Downey P, Parrish R, MacDonald J, et al. Combined in vitro and in vivo T lym- phocyte depletion for the control of graft- versus-host disease following haploidentical marrow transplant. Transplantation. 1996; 61(5):738-745.
7.Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regi- men for the treatment of advanced hemato- logic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113(19):4771-4779.
8. Kanda Y, Oshima K, Asano-Mori Y, et al. In- vivo alemtuzumab enables haploidentical human leukocyte antigen-mismatched hematopoietic stem-cell transplantation without ex vivo graft manipulation. Transplantation. 2005;79(10):1351-1357.
9. Aversa F, Terenzi A, Tabilio A, et al. Full hap- lotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol. 2005;23(15):3447-3454.
10. Lu D-P, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/hap- loidentical blood and marrow transplanta- tion can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065.
11. Wang Y, Liu D-H, Liu K-Y, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia. Cancer. 2013;119(5):978-985.
12.Luznik L, Jalla S, Engstrom L, Iannone R, Fuchs E. Durable engraftment of major his- tocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98(12):3456-3464.
13. O’Donnell P, Luznik L, Jones R, et al. Nonmyeloablative bone marrow transplan- tation from partially HLA-mismatched relat- ed donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002;8(7):377-386.
14.Santoro N, Ruggeri A, Labopin M, et al. Unmanipulated haploidentical stem cell transplantation in adults with acute lym- phoblastic leukemia: a study on behalf of the Acute Leukemia Working Party of the EBMT. J Hematol Oncol. 2017;10(1):113.
15.Srour SA, Milton DR, Bashey A, et al. Haploidentical transplantation with post- transplantation cyclophosphamide for high- risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2017;23(2):318-324.
16. Iskra Pusic, Steven Z. Pavletic. Challenges in conducting studies in chronic graft-versus- host disease. Clin Hematol Int. 2019;1(1):36- 44.
17. Holtan SG, DeFor TE, Lazaryan A, et al. Composite end point of graft-versus-host disease-free, relapse-free survival after allo- geneic hematopoietic cell transplantation. Blood. 2015;125(8):1333-1338.
18. Ruggeri A, Labopin M, Ciceri F, Mohty M, Nagler A. Definition of GvHD-free, relapse- free survival for registry-based studies: an ALWP–EBMT analysis on patients with AML in remission. Bone Marrow Transplantation. 2015;51(4):610.
19. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant. 1995;15(6):825-828.
20. Lee SJ, Vogelsang G, Flowers MED. Chronic graft-versus-host disease. Biol Blood Marrow Transplant. 2003;9(4):215-233.
21.Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regi- mens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628-1633.
22. Hougaard P. Frailty models for survival data. Lifetime Data Anal. 1995;1(3):255-273.
23. Andersen PK, Klein JP, Zhang M-J. Testing for centre effects in multi-centre survival studies: a Monte Carlo comparison of fixed and random effects tests. Stat Med. 1999;18(12):1489-1500.
24. Mohty M, Bacigalupo A, Saliba F, et al. New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ trans- plants, stem cell transplants and autoimmu- nity. Drugs. 2014;74(14):1605-1634.
25.Ruggeri A, Sun Y, Labopin M, et al. Post- transplant cyclophosphamide versus anti- thymocyte globulin as graft- versus-host dis- ease prophylaxis in haploidentical trans- plant. Haematologica. 2017;102(2):401.
26. Kanakry C, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to post- transplantation cyclophosphamide. Sci Transl Med. 2013;5(211):211ra157.
27. Wang Y, Liu Q-F, Xu L-P, et al. Haploidentical versus matched-sibling trans- plant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016;22(14):3467.
28. Giebel S, Labopin M, Socié G, et al. Improving results of allogeneic hematopoi- etic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica. 2017;102 (1):139-149.
29. Pavlů J, Labopin M, Zoellner AK, et al. Allogeneic hematopoietic cell transplanta- tion for primary refractory acute lym- phoblastic leukemia: a report from the Acute Leukemia Working Party of the EBMT. Cancer. 2017;123(11):1965-1970.
30. Rashmika R. Potdar, Sorab Gupta, Sebastian Giebel, et al. Current status and perspectives of irradiation-based conditioning regimens for patients with acute leukemia undergoing hematopoietic stem cell transplantation. Clin Hematol Int. 2019;1(1):19-27.
31. Eder S, Canaani J, Beohou E, et al. Thiotepa- based conditioning versus total body irradi- ation as myeloablative conditioning prior to allogeneic stem cell transplantation for acute lymphoblastic leukemia: a matched-pair analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2017;92(10):997-1003.
32.Nagler A, Labopin M, Shimoni A, et al. Mobilized peripheral blood stem cells com- pared with bone marrow as the stem cell source for unrelated donor allogeneic trans- plantation with reduced-intensity condition- ing in patients with acute myeloid leukemia in complete remission: an analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 2012;18(9):1422-1429.
1598
haematologica | 2021; 106(6)